No Data
No Data
Rani Therapeutics to Participate in September Investor Conferences
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$12m Last Week
HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $9
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $9
H.C. Wainwright analyst Mitchell Kapoor maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and adjusts the target price from $13 to $9.According to TipRanks data, the analyst has a success
Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)
Express News | Rani Therapeutics Holdings, Inc. : H.c. Wainwright Cuts Target Price to $9 From $13